Richard Buka/X
Sep 23, 2025, 06:40
Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
Richard Buka, Chair of HaemSTAR, shared on X:
”Bit of pharma news here. CSL Behring have announced a colab with Dutch biotech, VarmX.
VarmX have been working on a very exciting molecule that is an antidote oral FXa inhibitors like rivaroxaban and apixaban.
What is this molecule? And why is it worth a potential $1.7bn?”
Stay updated with Hemostasis Today.
-
Jul 6, 2026, 04:36Sarah Richardson: On Capitol Hill, Speaking Up for Patients
-
Jul 5, 2026, 23:26Nominations Now Open for the First Nations Stroke Excellence Award – Stroke Foundation
-
Jul 5, 2026, 22:51Shahzaib Akram: What Are We Actually Seeing When a Sickling Test Goes Positive?
-
Jul 5, 2026, 21:474 Tips for Exercising with A Bleeding Disorder – Haemophilia Foundation Australia
-
Jul 5, 2026, 21:06Heghine Khachatryan: Toward Personalized Management of Glanzmann Thrombasthenia
-
Jul 5, 2026, 21:06Priyanka Kumari: IV Fluids and Isotonic Solution
-
Jul 5, 2026, 21:05Ahmed Rizq: Would You Thrombolyse a Stable Patient?
-
Jul 5, 2026, 21:03Emmanuel Obeng Ofori: Diagnosing Anaemia – Why Treating the Root Cause Matters More Than Simply Raising the Haemoglobin
-
Jul 5, 2026, 21:02Mohit Koladia: The Pharmacist’s Role in Stroke Prevention for Atrial Fibrillation